Merck shares were down on Thursday after sales of two of its most important products fell short of Wall Street estimates. Sales of Merck’s aging megablockbuster Keytruda were $8.1 billion in the third ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Merck stock reflects a mix of steady revenue growth from oncology and vaccines and ongoing investment in research. Recent results highlight the impact of Keytruda and Gardasil on the companys top line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results